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Cre recombinase is extensively used to engineer the genome of experimental animals. However, its usefulness is still limited by
the lack of an efficient temporal control over its activity. We have recently developed a conceptually new approach to regulate
Cre recombinase, that we have called Dimerizable Cre or DiCre. It is based on splitting Cre into two inactive moieties and fusing
them to FKBP12 (FK506-binding protein) and FRB (binding domain of the FKBP12-rapamycin associated protein), respectively.
These latter can be efficiently hetero-dimerized by rapamycin, leading to the reinstatement of Cre activity. We have been able
to show, using in vitro approaches, that this ligand-induced dimerization is an efficient way to regulate Cre activity, and
presents a low background activity together with a high efficiency of recombination following dimerization. To test the in vivo
performance of this system, we have, in the present work, knocked-in DiCre into the Rosa26 locus of mice. To evaluate the
performance of the DiCre system, mice have been mated with indicator mice (Z/EG or R26R) and Cre-induced recombination
was examined following activation of DiCre by rapamycin during embryonic development or after birth of progenies. No
recombination could be observed in the absence of treatment of the animals, indicating a lack of background activity of DiCre
in the absence of rapamycin. Postnatal rapamycin treatment (one to five daily injection, 10 mg/kg i.p) induced recombination
in a number of different tissues of progenies such as liver, heart, kidney, muscle, etc. On the other hand, recombination was at
a very low level following in utero treatment of DiCre6R26R mice. In conclusion, DiCre has indeed the potentiality to be used
to establish conditional Cre-deleter mice. An added advantage of this system is that, contrary to other modulatable Cre
systems, it offers the possibility of obtaining regulated recombination in a combinatorial manner, i.e. induce recombination at
any desired time-point specifically in cells characterized by the simultaneous expression of two different promoters.
Citation: Jullien N, Goddard I, Selmi-Ruby S, Fina J-L, Cremer H, et al (2007) Conditional Transgenesis Using Dimerizable Cre (DiCre). PLoS ONE 2(12):
e1355. doi:10.1371/journal.pone.0001355
INTRODUCTION
The technology of gene inactivation through homologous
recombination has, since its introduction in the late eighties,
boosted immensely our understanding of the role of a great
number of genes. However, it has been progressively realized that
the interpretation of the results may be complicated by diverse
factors such as differences among various inbred mouse lines,
existence of compensatory adaptations, redundancies etc. More-
over, the modifications induced by the inactivation of a given gene
at an early developmental stage (the most extreme modification
being the lethality induced by the inactivation) may also interfere
with, and make often impossible, the evaluation of a possible late
role of that gene.
One way to avoid some of these problems is to have a temporal
regulation of the inactivation and be able to induce it at any
desired time-point. The introduction of the Cre/LoxP system has
made this approach possible. Cre is a site specific recombinase that
catalyzes the excision of a DNA segment flanked by two identical
short (34 bp) asymmetric sequences, called LoxP, of same
orientation, introduced into the genome by the experimenter.
When that portion of DNA corresponds to a crucial part of the
gene, the excision will lead to its inactivation [1]. Conditional
inactivation has become a real possibility when solutions have
been worked out for the in vivo regulation of Cre activity [2–5].
A first, ‘‘natural’’ approach to regulate Cre activity, and through it
gene inactivation, is to put it under the control of a cell-type specific
promoter. In that case one may obtain a spatial (cell-type dependent)
regulation of Cre, that can even display a specific temporal pattern if
the given promoter is activated only at a certain developmental stage
or in a certain physiological situation [6–8].
The activity of Cre can also be dependent on an inducer given
by the experimenter, and in that case one has the possibility of
switching on Cre in any cell type. For that, two basic approaches
have been worked out in the last few years: placing Cre under the
control of a regulatable promoter or use a fusion protein to obtain
a modulation of Cre activity by steroids.
The first option relies most of the times on the now classical
tetracycline-regulatable system worked out by Bujard and his
colleagues [9–12]. In that case the regulation of Cre is at the
transcriptional level, and the reliability of the system is dependent
on the tightness of the regulation of the promoter, i.e. its leakage
when not activated, and the level of maximal activity after
induction. Unfortunately, in many cases these systems are
somewhat leaky, which means, for the utilization we are
considering, that inactivation of the gene may occur spontane-
ously, before one would like to induce it experimentally.
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The second approach is based on the fact that the fusion of the
hormone-binding domain of the progesterone or estrogen steroid
receptors with Cre will make the biological activity of the latter
dependent on the steroid in the sense that the absence of the latter
keeps the enzyme in a cellular compartment physically separated
from the one in which its substrate is located [13–16]. Indeed, in
the absence of the steroid, the fusion protein is sequestered in the
cytoplasm of the cell by heat-shock proteins, and it is only
following the addition of the steroid that the complex dissociates
and Cre is able to enter the nucleus where it can combine with its
substrate, i.e. chromosomal DNA, and exert its activity. Note that
this approach can be combined with the previous one, allowing a
combined cell-type dependent and temporal control of recombi-
nase activity [17–19]. However, similar to the previous solution,
these systems may be leaky. Moreover, induction of Cre activity
within the central nervous system is not very efficient [13,20,21].
Last, but not least, the steroids that are used for induction can
exert physiological effects of their own [22,23].
We have recently developed a conceptually new approach to
regulate Cre recombinase, that we have called Dimerizable Cre or
DiCre [24]. DiCre is based on the functional complementation,
using ligand-induced dimerization [25], of two inactive Cre
moieties that can be associated by rapamycin through cross-linking
the protein fragments FKBP12 (FK506-binding protein; [26]) and
FRB, the ligand binding domain of FRAP (FKBP12-rapamycin
associated protein; [27]) linked to the Cre moieties. DiCre has
been validated in vitro and shown to be reliable, offering a low
background activity and high-level induction resulting in charac-
teristics that were better than that of a steroid-regulated form of
Cre. Given its good in vitro performance, it represents a promising
new tool that could offer an alternative to existing approaches for
conditional transgenesis. Moreover, relative to other approaches, it
offers the unique potential, being based on the coexpression of two
separate Cre fragments, to achieve ‘‘combinatorial’’ or ‘‘intersec-
tional’’ transgenesis [4]. The aim of the present work is to validate
this tool for such in vivo uses.
RESULTS
Targeting DiCre
DiCre requires the simultaneous expression in the cell of two
inactive Cre moieties that can functionally complement each other.
In our previous in vitro work, aimed at developing this system, we
have examined several combinations of N- and C-terminal Cre
moieties, differing in their length and/or in the linkers attaching
FKBP12 (or FRB) to them [24]. This characterization indicated that
these combinations differ in their background activity and/or the
level of activity obtained following dimerization. We assumed that
for conditional trangenesis it was important to aim at having the
lowest possible background expression level, even at the price of
having a somewhat lower induced activity. Thus, among the
different combinations tested, the Cre59.F2/Cre60.F2 combination,
that in our tests resulted in the lowest background, but still with a
reasonably good activation level, was chosen for the in vivo tests of the
system. As detailed previously [24], Cre59.F2 corresponds to the N-
terminal moiety (aa 19–59) of Cre to which FKBP12 is fused through
the flexible linker F2, while Cre60.F2 corresponds to the C-terminal
moiety of Cre (aa 60–343) to which FRB is fused through the same
flexible linker F2.
The expression of DiCre in vivo is complicated by the fact that
this system requires the simultaneous expression of two constructs
in the organism. With a classical transgenic approach that would
imply a relatively tedious mating scheme using three mouse lines
to bring the three constructs (the two components of DiCre plus
the Cre-target construct) into the same animals. A way to simplify
the experimental setup is to obtain a genetic linkage of the two
components of DiCre. Rather than using a bicistronic construct
and classical transgenesis, an approach that seemed less reliable,
we decided, to achieve that aim, to express DiCre in vivo by
homologous recombination, introducing a bicistronic construct
containing its two components into a known locus. For that, we
have chosen the Rosa-26 locus, that has been used extensively for
several years to express foreign genes in mice, and for which
extensive experience and molecular tools were available [28–30].
Details of the targeting construct are given on Figure 1A.
Following its successful insertion, the C-terminal component of
DiCre is expressed under the control of the Rosa-26 promoter,
while the expression of the N-terminal component is controlled by
the strong CAG promoter. In light of the ubiquitous expression
and the absence of silencing of genes expressed from this locus,
documented both during development and following birth [30], it
was felt that this approach would ensure a generalized and reliable
expression of DiCre. Note that a second promoter (PGK) with a
downstream hygromycin-resistance gene, used for selection of
successfully targeted ES cells, will also be present in the locus
following targeting. However, this cassette has been removed
secondarily from the genome by crossing F1 animals with Flpe-
expressing mice [31] and is not present in the final lines presented
here.
DiCre activity in targeted ES cells
Following the obtention of clones of successfully targeted ES cells
and before using them for blastocyst injection to obtain conditional
deleter mice, we wished to test that DiCre was functional in these
clones. Cells were transfected with an indicator construct, pcDNA3-
CALNLZ [32] that expresses the ß-galactosidase reporter gene in
transfected cells conditionally, dependent on the Cre-mediated
excision of a neomycin resistance-STOP-pA cassette inserted
between it and a CAG promoter (Fig. 2A). Following G418
selection, we obtained several subclones for the DiCre-containing ES
clones. As shown on Figure 2B, there was a complete lack of
expression of ß-galactosidase in the cells in the absence of inducer,
indicating that background activity in these conditions is even lower
than that we have observed earlier in fibroblasts. On the other hand,
exposure of the cells to the inducer (20 nM of the rapamycin analog
AP23102 for three days) led to the appearance of ß-galactosidase
activity in close to 100% of undifferentiated cells, indicating that the
system does work in ES cells. Note, however, that ß-galactosidase
activity was lower or absent in flat cells, presumably engaged in some
kind of differentiation pathway and surrounding the compact
aggregates of undifferentiated ES cell. This aspect has not been
pursued further.
Following this validation of the DiCre system, the initial targeted
ES cells (i.e. not containing the indicator CALNLZ construct) were
used for blastocyst injection. Several founder mice were obtained
and used to establish mouse lines (called in the followings DiCre
lines) after excision of the hygromycin-resistance cassette through
mating of F1 mice with an Flpe-expressing deleter line.
Characterization of DiCre in adult animals
In a first series of test, DiCre mice were mated with Z/EG
transgenic indicator mice to obtain double transgenic mice. The
Z/EG transgene is similar to the CALNLZ construct depicted on
Fig. 2A, except for the stuffer sequence that codes for LacZ and
the gene expressed following the excision of the stuffer sequence
that is EGFP [33]. Thus, cells of these animals are LacZ+ in the
absence of recombination and green fluorescent following Cre-
Conditional Transgenesis
PLoS ONE | www.plosone.org 2 December 2007 | Issue 12 | e1355
mediated excision. Young adult double transgenic progenies
resulting from this mating were treated with the inducer (daily
injection of 10 mg/kg rapamycin for five days) and sacrificed
5 days after the end of the treatment. In the absence of treatment
no fluorescent cells could be detected on tissue sections prepared
from a number of tissues (brain, pituitary, heart, lung, liver,
kidney, skin, striated muscle). In treated animals EGFP-positive (as
confirmed by immunohistochemistry, results not shown) green
fluorescent fibers, indicating that recombination has taken place,
were present only in the heart, and surprisingly, recombined green
fluorescent cells could be detected in no other tissues (Fig. 3).
Because of the low number of recombined cells, this switch on of
EGFP expression could not be correlated to a significant decrease
of the level of X-gal staining in the heart. Note that in untreated
animals, strong and definite X-gal staining was observable only in
the heart and muscle.
To control and complement these results using another
indicator mouse line, DiCre mice were mated with R26R animals
[29] and the existence of recombination examined on tissue
sections by X-gal staining. Again, no labeled cells were observed in
the absence of treatment. On the other hand, and contrary to what
had been observed with the Z/EG indicator line, recombination
was widespread and could be observed in a number of tissues after
treatment of the in DiCre6R26R animals with the inducer (Fig. 4).
Thus, blue cells could be observed in heart, kidney, liver, testis,
adrenals, fat tissue (not shown), lung, pituitary (adenohypohysis),
spleen. However, the degree of staining differed greatly among
these tissues, being quite dense in the liver where up to 30–40% of
the cells were blue, intermediate in the heart and kidney, and low
(only a few cells per sections) in the other tissues. Moreover,
staining was not necessarily uniform in tissues with complex
architecture, such as in the kidney where staining was more
concentrated in the region of renal papilla and much less in the
cortex, in the lung with staining detectable only in the alveolar
epithelium, or in the testis, where only interstitial Leydig cells
showed staining. No staining could be observed in the muscle,
brain, or epidermis. The pattern of recombination was the same
when higher doses of rapamycin were used (up to 40 mg/kg,
results not shown).
To evaluate the number of rapamycin injections needed to
induce DiCre-mediated recombination, mice were treated with
different drug regimens, i.e. daily injections of 10 mg/kg
rapamycin for one, three or five days. In parallel, higher doses
(5620 or 5640 mg/kg) of rapamycin were also tested. Animals
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Figure 1. Targeting strategy for the creation of DiCre ES cells. A: Scheme of the targeting vector and of the Rosa26 locus following homologous
recombination. ‘‘B’’ and ‘‘R’’ stand, respectively, for the BamHI and EcoRV sites that are used when screening ES cells clones for correct insertions
using Southern blots and the probes indicated on the scheme. Fragments amplified when genotyping animals are also represented B: Representative
examples of Southern blots obtained from wild type ES cells or clones with correct recombination, using the probes shown on the schemes above.
doi:10.1371/journal.pone.0001355.g001
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were sacrificed ten days after the last injection and recombination
rate was quantitatively evaluated in the liver using Southern blots.
The results indicate that the degree of recombination is equivalent
for five or three injections and somewhat lower with a single
injection (Fig. 5). It should be noted also that the use of the highest
dose of rapamycin (40 mg/kg) seems to increase the degree of
recombination.
Characterization of DiCre during development
Although some recombination could be observed in DiCre6R26R
progenies following rapamycin treatment during their intrauterine
development (E13–14 or E18–19), its level was definitely lower
(only a few cells per section) relative to that observed following
postnatal treatment and restricted to the liver, kidney and heart
(results not shown).
To test whether the absence of recombination in embryos could
be due to an insufficient passage of the dimerizer through the
placental barrier, primary cultures were prepared from CNS, liver,
heart of E15 DiCre6R26R embryos. Cultures were also prepared
from the carcass of embryos using protocols described for
obtention of Mouse Embryonic Fibroblasts [34] resulting in a
mixed primary culture we call ‘‘MEF’’ and that contains, besides
fibroblasts, other types of cells, such as myocytes and fused muscle
fibers etc. Cre activity was induced by adding 10 nM AP23102
(DiCre6R26R cells) at 3 DIV and LacZ activity was tested four
days later. Results were similar to what had been observed in vivo,
i.e. some recombined cells could be observed among hepatocytes
or cardiomyocytes obtained from DiCre6R26R embryos, but
their proportion was very low (Fig. 6.).
Expression of DiCre
Evaluation of the level of transcripts, using Northern blots (Fig. 7A)
or qPCR (Fig. 7B), in ES cells clones used to establish the DiCre
mouse lines or in different tissues from young adult DiCre mice
indicated that the level of transcription of Cre60.F2 from the Rosa26
promoter was relatively homogeneous and at comparable levels
among these different tissues, except for the brain in which
transcription seemed to be somewhat lower. For Cre59.F2 the level
of expression, driven by the CAG promoter, was considerably higher
than that mediated by the Rosa26 promoter for Cre60.F2. However,
while for the Cre59.F2 transcript levels in the liver and ES cells were
similar, the levels observed in the skin, kidney and brain were
considerably lower. In tissues from E15 embryos, the level of
Cre60.F2 transcription was diminished relative to the adult levels
and transcription of Cre59.F2, controlled by the CAG promoter,
was also found to be considerably decreased (Fig. 7C and 7D).
Figure 2. DiCre are functional in targeted ES cells. A: Scheme of the
CALNLZ indicator construct used to test the functionality of Cre. B: ß-
galactosidase expression, as revealed by the blue X-Gal reaction
product, in ES cells with correct insertion of the DiCre construct into
the Rosa26 locus and stable transfection of the pcDNA-CALNLZ
construct. Cells are tested without (‘‘Control’’) or following exposure,
for three days, to 20 nM of the dimerizer AP23102.
doi:10.1371/journal.pone.0001355.g002 Figure 3. Induction of Cre-mediated recombination in DiCre6Z/EG
mice. A: The presence of recombination is shown by EGFP expression in
the heart of DiCre6Z/EG adult animals ten days after the end of
treatment with the inducer (5610 mg/kg rapamycin i.p.). B: In the
absence of rapamycin treatment no specific fluorescence can be seen.
doi:10.1371/journal.pone.0001355.g003
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Figure 4. Induction of Cre-mediated recombination in various tissues of DiCre6R26R mice. The presence of recombination is shown by ß-
galactosidase expression, as revealed by the blue X-Gal reaction product, in various tissues of adult DiCre6R26R animals ten days after the end of
treatment with the inducer (5610 mg/kg rapamycin i.p.). Bars represent 100 mm. The insert for the liver shows the total absence of recombination in
the absence of rapamycin treatment.
doi:10.1371/journal.pone.0001355.g004
Figure 5. Dose-dependence of DiCre activation in vivo. A: Southern blots, using a LacZ probe, prepared from the liver of adult DiCre6R26R animals
ten days following 5610 mg/kg, 3610 mg/kg, 1610 mg/kg, 5620 mg/kg or 5640 mg/kg i.p. rapamycin treatment, with two or three animals for
each condition. The upper band (R) corresponds to the R26R allele after recombination, the lower band (NR) to the non-recombined allele. B:
Quantification of the degree of recombination, as estimated by image analysis of the blot shown above.
doi:10.1371/journal.pone.0001355.g005
Conditional Transgenesis
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DISCUSSION
The aim of the present work was to assess the functionality of DiCre
in vivo and its ability to be used to establish conditional deleter mice.
Our results indicate that DiCre has indeed the potential to be used
for conditional transgenesis and that DiCre mice could complement,
and represent an alternative to, already existing approaches.
To be used for a general deleter strain, a modulatable Cre should
fulfill several conditions. The two most important ones are, first, to
have a low background activity, i.e. to induce no recombination in
the absence of the inducer, and second, to lead, upon treatment with
the inducer, to recombination in the different tissues of the animal.
Additional conditions are that this induced recombination should be
general within and among tissues, be independent of the
developmental stage of the animals, and finally, that the inducer
should not exert physiological effects on its own. It should be stressed
that none of the existing systems to date fulfill all these criteria.
Indeed, they often display some background activity, and their
activation is usually mosaic, especially at later stages of development
or in postnatal animals. Moreover, the most often used inducer,
tamoxifen, has developmental and endocrine effects on its own that
may present problems in some experimental situations [22,23].
Results of the present study show that DiCre fulfills the first two
conditions. Thus, we have not observed any recombination in the
absence of treatment of the animals with rapamycin in the different
tissues examined. This finding is in line with the fact that the DiCre
variant that we have used to establish the DiCre mouse line
corresponds to one that displayed a background activity among the
lowest in our previous in vitro studies [24], and that it had no
discernable background activity in ES cells (present study).
Treatment with rapamycin, on the other hand, leads to recombi-
nation, albeit at different levels, in a number of tissues. On the basis
of these findings, it can be concluded that DiCre represents a
potential alternative for the creation of general deleter mouse strains.
It should be noted that a major advantage of DiCre over
existing approaches is that, given its mechanism of action, its use
may allow to create more complex experimental schemes. Indeed,
using cellular promoters to control activity of Cre is a frequently
used approach to restrict recombination to cells in which that
promoter is active. In the case of DiCre, it will be possible to place
each Cre moieties under the control of two different cellular
promoters, targeting recombination to cells in which these two
promoters are simultaneously active, and, moreover, superpose a
temporal regulation to this targeting. The possibility of this kind of
‘‘combinatorial’’ or ‘‘intersectional’’ recombination, without the
temporal regulation that DiCre allows however, was evocated in
the case of the alpha-complementation of Cre fragments worked out
a few years ago [35], but, contrary to DiCre, this system could not be
shown to work in vivo (E. Casanova, personal communication). Note
that a variant of this system, based on a leucine-zipper mediated
unconditional complementation of Cre fragments has recently been
shown to work in vivo [36]. However, comparison of this system with
DiCre is not straightforward, as its performance has been
documented only for the pancreas, where it led to a mosaic
recombination. Moreover, given the unconditional character of the
complementation, the recombination observed reflects recombina-
tion occuring during embryonic development, while DiCre could
not be efficiently activated in utero (see also below).
While the present data demonstrate that DiCre works in vivo,
they also show that induction of DiCre presents several aspects,
related to the conditions listed above, that should be improved to
ameliorate the system and make it more performant.
A first point is that the level of recombination brought about by
the activation of DiCre was found to be highly variable both
between and within tissues. This finding is not specific for DiCre,
as it has been noted for all Cre constructs used to establish deleter
mice. Thus, in similar experiments done with another deleter line
expressing a tamoxifen-regulated Cre construct, we have found in
adult animals a very similar pattern of recombination using the
Cre-indicator lines used also in the present study (Jullien et al.,
submitted). This general variability might be related to the
heterogeneity, between different tissues or in different cell
populations of a given organ, in the characteristics of the indicator
construct in its genomic context, such as a variable expression or
silencing of the indicator transgene determined by neighboring
host sequences, different local chromatin structures determining
accessibility of the recombination target, etc. The same factors
may also explain that different recombination patterns can be
observed depending on the Cre indicator strain used. This
influence of strains has been shown here by the major difference
between our results obtained using the Z/EG and the R26R lines,
but it has also been documented by other groups [20,21,37,38].
An additional factor influencing the level of recombination
(although not determining it strictly, as shown by the lack of clear
correlation between the level of DiCre expression and the degree
of recombination found in the different tissues, compare Figs. 4.
and 7.) is the level of expression of the specific Cre construct used.
Figure 6. Induction of Cre-mediated recombination in primary cultures of embryonic tissues of DiCre6R26R mice. The presence of recombination
is shown by ß-galactosidase expression, as revealed by the blue X-Gal reaction product on the bright-field (upper row) and phase contrast (lower row)
images of the same fields, in primary cultures prepared from various tissues of DiCre6R26R E15 embryos. Cultures were exposed between 3 and
7 day in vitro to 10 nM AP23102.
doi:10.1371/journal.pone.0001355.g006
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Figure 7. Expression of the DiCre constructs in tissues of adult or embryonic transgenic animals. A: Northern blots obtained from DiCre ES cells or
tissues from young adult DiCre transgenic animals (two independent samples for each), indicating the level of mRNA for the indicated transgenes. B:
Expression level, relative to that measured in the liver, of the same transgenes in tissues of adult animals, as measured by qPCR (means +/2 SEM,
n = 3–5). C: Northern blot, and D: qPCR analysis, as in panels 7A and 7B, from embryonic (E15) tissues and adult tissues used as comparison. Note that
the adult tissues used here were not the same as those shown on panels 7A and 7B.
doi:10.1371/journal.pone.0001355.g007
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This aspect may have a more important role in the case of DiCre,
given that activation of DiCre is a ternary reaction involving
rapamycin and the FKBP- and FRB-fused Cre moieties. Thus, it
seems likely that to obtain an activity level comparable to that
achieved using e.g. a classical steroid-activated version of Cre, a
higher intracellular concentration of the DiCre components
should be attained. This is especially true for the rate-limiting
moiety of DiCre, which, in the present setup, corresponds to the
Cre60.F2 fragment driven by the relatively weak Rosa26 promoter
and that displays the lower level of transcription relative to the
other moiety (see Fig 7.). This hypothesis might be explored in the
future through the use of a promoter stronger than the Rosa26
promoter. A second parameter specific to the Cre constructs and
that determines, in conjunction with the level of expression, the
success of recombination, is its intrinsic activity. Thus, the different
DiCre variants that we have tested previously in vitro have been
observed to have different intrinsic activities [24]. As mentioned
above, the variant tested here (Cre59.F2/Cre60.F2) possesses an
intrinsic activity that is lower than that of other variants, but was
chosen nevertheless for its low background activity and good
activation ratio. Using a DiCre variant with a higher intrinsic
activity (such as the Cre104.F5/Cre106.F5 combination, see [24])
might lead to a higher recombination efficacy in vivo, and that
option will also be explored in the future. Note that using another
DiCre variant presents the risk of having a somewhat higher
background activity. In fact, there should be an interplay between
the strength of the promoter and the DiCre variant used and it
may well be that several combinations will have to be explored to
find an optimal combination. Thus, the presently used variant, as
controlled by the weak Rosa26 promoter displayed no background
in vivo, while in our previous in vitro studies, when it was controlled
by a strong viral promoter (CMV) it had some, even if quite low,
background activity.
Finally, one might also invoke a possible variable distribution of
rapamycin to explain the observed differences between tissues.
However, insofar that the drug is known to be rapidly and evenly
distributed among tissues [39,40], this factor is unlikely to play a
significant role in the observed variability.
DiCre-induced recombination during embryonic development
was found to be very weak, if not absent, in most tissues. Our
Northern blot analysis indicates that the level of expression of
DiCre in embryonic tissues, especially its component controlled by
the CAG promoter, is significantly lower than that found in young
adults. The reasons of this are not clear, but it may explain the lack
of recombination that we have observed both in vivo and in the ex
vivo tissue culture conditions, and use of other promoters to control
DiCre expression might solve this problem too. Note, however,
that other factors might also contribute to the bad efficacy of
DiCre in embryos. Thus, the bioavailability of rapamycin might
be at an insufficient level in the embryos. Rapamycin is known to
cross the placental barrier [41], but the level it reaches in the
embryo is not known. However, our ex vivo culture experiment
indicates that, while this factor may play a role, it may not be the
most important and factors specific to the embryonic tissue might
be involved. Thus, level of cellular uptake in embryonic cells might
be not sufficient to ensure a high enough level of the drug within
cells or, alternatively, the drug might be titrated out by the high
endogenous FKBP12 level existing in embryos that could also,
moreover, compete out the FKBP-linked Cre moiety ([42];
personal observations). The validity of these hypotheses will have
to be evaluated in future experiments.
Besides these potential problems more specific to embryos,
rapamycin presents other problems too. Indeed, this drug has,
through its interaction with endogenous FRAP, numerous actions
of its own: immunosuppression, interference with cell division,
teratogenicity [43,44]. Given these pharmacological actions, use of
rapamycin analogs (rapalogs) devoid of such side effects would be
highly desirable. Several such analogs, based on modifications of
the FRB binding region of rapamycin, have been developed in the
last few years [45–47]. They have in common not to recognize the
endogenous target of rapamycin (FRAP), but to recognize a
mutated form of this protein, such as the T2098L mutant used for
the elaboration of DiCre, allowing its dimerization to FKBP12.
While this mutation conserves the capacity of FRB to be dimerized
also by rapamycin, it binds with high affinity these rapalogs, such
as the AP23102 or AP21967 compounds that we have used for our
in vitro characterization of the system. We have shown that these
two drugs, while being good inducers of DiCre, have indeed less
side effects insofar that they do not influence, contrary to
rapamycin, cell division in vitro. This suggested to us that for in
vivo uses they could represent a good alternative, devoid of adverse
side effects, to rapamycin. Unfortunately, preliminary experiments
have shown us that these two rapalogs are inefficient in vivo, as
treatment of DiCre6R26R animals, be it during development or
postnatally, induced, even at relatively high doses, considerably
less recombination than rapamycin, due, maybe, to unfavorable
pharmacokinetics of these drugs. Note that another rapalog, iRap,
that is closely related to AP21967 [45], was found to activate
DiCre in DiCre6R26R mice with the same efficacy as rapamycin
(results not shown). However, insofar as it displays an affinity
towards wild-type FRB that is comparable to that it has for the
mutated form of FRB, it is likely to have the same side effects as
rapamycin, and therefore cannot really be considered as a suitable
option for the replacement of rapamycin.
Thus, alternative rapalogs will have to be tested to bypass the
toxicity of rapamycin and improve these drug-related aspects of
DiCre. A first option is to continue to explore drugs developed
according to the logic presented above, i.e. drugs able to dimerize
FKBP12 and a mutated form of FRB. A possible alternative is to
modify the dimerizable partners fused to the Cre moieties
themselves and use a mutated FKBP12 only, such as the F36V
mutant, in conjunction with homodimerizer drugs that do not
interfere with endogenous FKBP12 but have good pharmacoki-
netic characteristics [47–49]. Note that, due to the inability of
these drugs to bind endogenous FKBP12, the latter option may
present the added advantage of having a better efficacy during
embryonic development (see above). It should be underlined,
nevertheless, that while rapamycin seems to be quite toxic during
development and in neonates, it seems to be well tolerated in older
animals where, moreover, only one to three injections are required
to activate DiCre, and thus it could be used, given appropriate
controls, as an inducer of DiCre in adult animals.
In conclusion, DiCre represents a valuable new option to
establish deleter mouse lines and achieve conditional transgenesis.
It has interesting and unique characteristics, such as the possibility
of achieving regulated combinatorial recombination. Future
studies should help ameliorating it and make it a generally usable
tool, in particular during development.
METHODS
Plasmid construction
The targeting construct is depicted on Figures 1A. It was
constructed by standard cloning techniques [50] and based on
the pRosa26.1 targeting vector, donated by Dr. P. Soriano, for
insertion into the Rosa26 locus. Cassettes inserted into this vector
were the Cre60.F2 and Cre59.F2 sequences for the expression of
DiCre [24], a hygromycin resistance cassette extracted from the
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p1710 vector (gift of Dr. J. Majors, St.Louis, MO), the PGK
promoter from pRosa26.1, and the CAG promoter extracted from
the pDRIVE-CAG vector (InVivogen, Toulouse, France). The
adenoviral splice acceptor sequence was recovered from the pSA-
ßgeo vector [51] donated by Dr. P. Soriano, the polyadenylation
signals (SV40 pA downstream of the Cre59.F2 sequence and
BGHpA downstream of the Cre60.F2 sequence) from pcDNA3.1
(Invitrogen, Cergy Pontoise, France).
The pcDNA-CALNLZ vector was constructed by inserting the
CALNLZ cassette [32] into pcDNA3.1 in antiparallel orientation.
ES cell culture and manipulation
Procedures for the manipulation of ES cells were based on
published protocols [34]. R1 ES cells [52] were grown on
mitomycin C-arrested STO fibroblasts expressing the neomycin
and hygromycin resistance genes (gift of Dr. E. Robertson, San
Diego, CA) in DMEM supplemented with 15% FCS and leukemia
inhibitory factor (ESGRO, 1000 U/ml, Chemicon, Chandlers
Ford, UK). Following electroporation of 107 cells with 20 mg of the
linearized targeting construct, selection was performed with
150 mg/ml hygromycin B for 8 days. Individual drug resistant
clones were picked manually and transferred to 96-well microtiter
plates, expanded and split. One of the resulting plates was frozen
down and screening of clones was performed by Southern blots on
the other plate, following digestion of isolated genomic DNA with
BamHI or EcoRV and using ‘‘Rosa26-59’’, a 502 bp probe,
located upstream of the insert and amplified from the Rosa26
locus using the primers 59-GATAGGAACTGGAAAACCA-
GAGGA-39 and 59-GTAAGGGTCCAACAGAAAAGAGA-39
(Fig. 1A.). A secondary Southern blot analysis, done on the
positive clones of the first screen, allowed evaluating the integrity
(using ‘‘Rosa26-39’’, a 709 bp probe located at the 39 border of the
insert) and unicity (using ‘‘Cre’’, a 732 bp probe internal to Cre) of
the insert. Location of the restriction site and probes, as well as a
representative example of Southern blots, are indicated on Fig. 1.
Correct clones were re-thawn, expanded and frozen down till their
further use. Chimeras were produced by injection of ES cells into
blastocysts obtained from C57Bl/6 mice (Charles Rivers, Lyon,
France)
To test functionality of the regulatable Cre constructs inserted
into the Rosa-26 locus, recombined ES cell clones were re-
transformed by electroporation with the linearized pcDNA-
CALNLZ construct, selected with 250 mg/ml G418 for one week
and subcloned before testing.
Primary culture
Primary cultures were prepared form E15 embryos. Dissected liver
and CNS tissues were digested 15 mins at 37uC in trypsin-EDTA,
heart 30 mins at 37uC in trypsin-EDTA followed by 30 mins in
collagenase. Following digestion, tissues were mechanically
dissociated in culture medium containing 0.01% DNAse and the
cells were plated onto polylysine-coated coverslips in DMEM/F12
(liver and neural cultures) or DMEM (heart cells) containing 10%
FCS. Mixed ‘‘MEF’’ cultures were prepared from the carcass of
the embryos digested for 45 mins in trypsin-EDTA with
intermittent shaking, dissociated and plated onto polylysine-coated
coverslips in DMEM with 10% FCS. Cells were grown in 5%
CO2:95% air at 37uC for three days before addition of the
inducers, grown for further 4 days and fixed using 2% parafor-
maldehyde in phosphate buffer (0.1M, pH 7.4). ß-Galactosidase
activity was revealed by incubating the fixed cells in PBS
containing 1 mg/ml X-Gal, 5 mM potassium ferricyanide,
5 mM potassium ferrocyanide, and 2 mM MgCI2.
Animal handling
Animals were maintained in standard conditions, with food and
water ad libitum and a 12 h:12 h dark:light photoperiod. The
hygromycin cassette from F1 recombinant DiCre mice was
eliminated by crossing with FLPe mice [31]. Mice were then
backcrossed for 2 generations onto C57Bl/6 background and then,
to facilitate subsequent characterization, intercrossed to obtain
homozygote lines. Mice were genotyped for the presence of the
transgene by PCR on tail DNA obtained by the ‘‘hot-shot’’
method [53].
Homozygote recombinant mice were mated with heterozygote
Z/EG [33] or homozygote R26R [29] Cre indicator mice.
Progenies born from mating with Z/EG mice were genotyped for
the presence of the Z/EG transgene by PCR on tail DNA.
Rapamycin (Sigma, St. Louis, MO, or LC Labs, Woburn, MA)
or the rapamycin analogs AP-23102 or AP-21967 (Ariad Inc.,
Boston, MS) were dissolved in N,N-dimethylacetamide (DMA)
and then diluted in a mixture of 4% DMA, 10% polythylene glycol
(average MW 400) and 17% polyoxyethylen sorbitane monooleate
(Tween 20). Injections were given intraperitoneally (i.p.).
Histology
Animals were deeply anaesthetized and sacrificed by transcardiac
perfusion of saline followed by 2% paraformaldehyde in phosphate
buffer (0.1 M, pH 7.4). When X-gal staining was to be performed,
the fixative contained 1 mM EDTA and 2 mM MgCl2. Following
3–5 h postfixation at room temperature, tissues were cryopro-
tected overnight at 4uC in 30% sucrose and frozen down for
preparation of 25 mm cryostate sections. EGFP expression was
examined by direct inspection of sections or following immuno-
staining using a polyclonal anti-GFP antibody (Molecular Probes,
Invitrogen, 1/5000) followed by a secondary, Alexa Fluor 594-
labelled, anti-rabbit antibody (Molecular Probes, Invitrogen, 1/
600). ß-Galactosidase expression was revealed by incubation of the
section in PBS containing 1 mg/ml X-Gal, 5 mM potassium
ferricyanide, 5 mM potassium ferrocyanide, 2 mMMgCI2, 0.01%
sodium deoxycholate, and 0.02% Nonidet P-40.
Northern blots and qPCR
Five mg total RNA, extracted by Trizol (Invitrogen) for tissues or
RNEasy (Qiagen) for cultured cells, were loaded onto a
formaldehyde/MOPS agarose gel, and transferred after migration
onto Hybond N+ membrane (Amersham). The Rosa26 driven
Cre60.F2 transcript was revealed by hybridization with a 732 bp
digoxigenin-labeled probe specific for C terminal Cre moiety; the
CAG promoter-driven Cre59.F2 transcript was hybridized with a
363 bp digoxigenin-labelled fragment of the Cre59.F2 CDS.
Hybridization, washing and revelation using CDP* were adapted
from Roche’s DIG membrane protocols.
Reverse transcription of 1 mg RNA was done using SuperScript II
and random primers as indicated by the manufacturer (Invitrogen).
qPCR was done using the SYBR-Green PCR master mix (Applied
Biosystems) and run onto an ABI Prism 7700 station. Specific
primers were designed with AmplifX (http://ifrjr.nord.univ-mrs.fr/
AmplifX). Calculations were done by the DDCt method [54] using
18S RNA as reference, after having determined, using dilution series,
that amplification efficiencies were homogeneous for the different
primer pairs and very close to 100%.
Southern blots
To quantify the degree of recombination of the R26R reporter
allele, genomic DNA was prepared from tissues following
proteinase K digestion, using standard procedures [50]. Following
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digestion by HindIII, that was determined previously to allow
discrimination of recombined and non-recombined R26R alleles,
migration and transfer to Hybond N+ membranes, Southern blots
were completed using a digoxigenin-labelled 890 bp for LacZ.
Blots were digitalized using a ChemiGenius II station (Syngene,
Cambridge, UK) and quantification of the native 16 bits gray level
files was performed using GeneTools (Syngene).
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